EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyse

Omecamtiv mecarbil for heart failure: Unpacking the latest systematic review and meta-analysis

Ramzi Ibrahim

International Journal of Cardiology and Cardiovascular Diseases · 2024

DOI: 10.46439/cardiology.4.028 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift International Journal of Cardiology and Cardiovascular Diseases, 2024. Verfasst von Ramzi Ibrahim.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In February 2023, a systematic review and meta-analysis of six randomized controlled trials (RCTs) with a total of 9,596 patients assessed the effectiveness and safety of omecamtiv mecarbil (OM) versus placebo in patients with heart failure with reduced left ventricular ejection fraction (HFrEF). HFrEF is a significant health problem associated with high morbidity and mortality worldwide. OM is a novel drug that targets cardiac myosin, a cytoskeletal motor protein responsible for converting chemical energy to mechanical force.

Zitieren

APA

Ibrahim, R. (2024). Omecamtiv mecarbil for heart failure: Unpacking the latest systematic review and meta-analysis. International Journal of Cardiology and Cardiovascular Diseases. https://doi.org/10.46439/cardiology.4.028

Vancouver

Ibrahim R. Omecamtiv mecarbil for heart failure: Unpacking the latest systematic review and meta-analysis. International Journal of Cardiology and Cardiovascular Diseases. 2024. doi:10.46439/cardiology.4.028

BibTeX
@article{Ibrahim2024,
  author = {Ibrahim, Ramzi},
  title = {Omecamtiv mecarbil for heart failure: Unpacking the latest systematic review and meta-analysis},
  journal = {International Journal of Cardiology and Cardiovascular Diseases},
  year = {2024},
  doi = {10.46439/cardiology.4.028}
}
Kostenlos starten →